FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Syndicate content

Prima BioMed to raise cash for ovarian cancer vaccine trial

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Australia's Prima BioMed plans to raise AU$38 million to fund late-stage trials of CVac, an immunotherapy ovarian cancer vaccine designed to be administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There are currently no maintenance-based therapy products commercially available for that indication, noted the developer in a release. The money, which will come in the form of an AU$18 million placement to shareholders and a AU$20 million share purchase plan, is slated to fund Phase III trials of the vaccine.

Prima plans to enroll 800 patients in its late-stage study across multiples sites in Europe, the U.S. and Australia. Enrollment will begin this summer, with data from the late-stage trial expected by 2013. "If statistical endpoints are successfully reached in the Phase III Trial, CVacTM will be well placed to become the world's first ovarian cancer immunotherapy treatment," the company noted in a release.

- here's Prima's release (.pdf)


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Prima BioMed   ovarian cancer vaccine  

Comments

Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.